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BACKGROUND & AIMS:
The best regimen to re-treat patients who do not respond to direct-acting antivirals (DAAs) and the feasibility of further shortening regimens is unclear. We assessed the efficacy and safety of the combination of the nucleotide polymerase inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the NS3/4A protease inhibitor GS-9857 in patients with hepatitis C virus genotype 1 infection. METHODS:
We performed an open-label trial at 32 sites in the United States and at 2 sites in New Zealand of 197 patients with genotype 1 hepatitis C virus infection, with or without compensated cirrhosis, who were treatment-naive or were treated previously with a DAA. Between March 2, 2015, and September 1, 2015, patients received sofosbuvir-velpatasvir (400 mg/100 mg in a fixed-dose combination) plus GS-9857 (100 mg) once daily for 6-12 weeks, plus ribavirin for 1 treatment group consisting of treatment-naive patients with cirrhosis. The primary end point was sustained virologic response 12 weeks after treatment (SVR12). RESULTS: Among treatment-naive patients without cirrhosis, 71% (24 of 34; 95% confidence interval [CI], 53-85) achieved SVR12 after 6 weeks of treatment and 100% (36 of 36; 95% CI, 90%-100%) achieved SVR12 after 8 weeks of treatment. Among treatment-naive patients with cirrhosis, 94% (31 of 33; 95% CI, 80-99) achieved SVR12 after 8 weeks of treatment and 81% (25 of 31; 95% CI, 63-93) achieved SVR12 after 8 weeks of treatment with ribavirin. Among DAA-experienced patients treated for 12 weeks, 100% without cirrhosis (31 of 31; 95% CI, 89-100) and 100% with cirrhosis (32 of 32; 95% CI, 89-100) achieved SVR12. The most common adverse events were headache, diarrhea, fatigue, and nausea. One patient (<1%) discontinued treatment because of adverse events. CONCLUSIONS: In a phase 2 open-label trial, we found 8 weeks of treatment with sofosbuvir-velpatasvir plus GS-9857 to be safe and effective in treatment-naive patients; 12 weeks was safe and effective in patients previously treated with DAAs. The combination was safe and effective in patients with or without compensated cirrhosis. Clinicaltrials.gov no: NCT02378935.
Keywords: Direct-Acting Antiviral Agent; NS5A; NS5B; NS3/4A. O f the 6 known genotypes of the hepatitis C virus (HCV), genotype 1 is the most common, affecting almost half of the estimated 130-150 million people with chronic HCV infection worldwide. 1, 2 Although genotype 1 HCV was long considered the most difficult to treat HCV infection, several highly effective and safe regimens involving combinations of recently approved direct-acting antivirals (DAAs) now are available for patients with genotype 1 HCV, regardless of treatment history and stage of liver disease. [3] [4] [5] [6] One clinical question that remains unanswered is the identification of retreatment regimens for patients who do not achieve sustained virologic response (SVR) with approved regimens of DAAs in which resistance-associated substitutions (RASs) may have emerged. Treatment-emergent RASs, particularly after exposure to NS5A inhibitors, have the potential to limit re-treatment options. 7 There is currently no approved regimen for patients who have failed an HCV regimen including an NS5A inhibitor. Current treatment recommendations for NS5A inhibitor-experienced patients suggest delaying therapy in those without urgent indications for treatment and, when treatment is necessary, long durations with the addition of ribavirin often are advised on the basis of minimal evidence. 8 One possible strategy to address the need for a salvage regimen is to combine highly potent DAAs with enhanced activity against RASs. Such a combination regimen additionally may allow for shortening of treatment duration in patients who have not been treated previously for HCV.
Sofosbuvir is a nucleotide analogue inhibitor of the HCV NS5B polymerase approved for the treatment of genotypes 1-6 HCV infection in combination with other agents. 9, 10 Velpatasvir is a novel HCV NS5A inhibitor with pangenotypic efficacy. 11 The combination of sofosbuvir and velpatasvir has been shown in phase 3 clinical trials to be highly effective and safe in treatment-naive and previously treated patients with HCV of all genotypes, including those with compensated and decompensated cirrhosis. [12] [13] [14] GS-9857 is a novel macrocyclic NS3/4A protease inhibitor with potent in vitro antiviral activity against genotypes 1-6 HCV and broad coverage of NS3/4A protease polymorphisms, including RASs associated with first-generation NS3/4A protease inhibitors. 15, 16 In a phase 1 trial, administration of 100 mg of GS-9857 to patients with genotypes 1-4 HCV resulted in median maximum reductions in HCV-RNA levels of 3 log 10 IU/mL or greater. 17 We assessed the efficacy and safety of 6-12 weeks of sofosbuvir-velpatasvir plus GS-9857 in treatment-naive patients and patients previously treated with DAAcontaining regimens with genotype 1 HCV, including those with compensated cirrhosis.
Materials and Methods

Study Design
This open-label, 2-cohort, phase 2 study was conducted between March 2, 2015, and September 1, 2015, at 32 sites in the United States and at 2 sites in New Zealand. Cohort 1 enrolled treatment-naive patients, and cohort 2 enrolled patients previously treated with regimens that contained an NS5A inhibitor alone, or 2 or more classes of DAAs. Cohort 1. At the time the study was initiated, 2 groups of treatment-naive patients were enrolled in cohort 1: a group of patients without cirrhosis, who received sofosbuvir-velpatasvir plus GS-9857 for 6 weeks, and a group of patients with cirrhosis, who received sofosbuvir-velpatasvir plus GS-9857 for 8 weeks. The protocol specified that if the rate of relapse among patients with cirrhosis who received 8 weeks of treatment was 10% or less, there was an option that another group could be enrolled to receive 6 weeks of treatment. This option was not exercised. Instead, preliminary results from these first 2 groups prompted us to amend the protocol to add 2 groups to this cohort: a group of patients without cirrhosis, who received 8 weeks of sofosbuvir-velpatasvir plus GS-9857, and a group of patients with cirrhosis, who received 8 weeks of sofosbuvir-velpatasvir plus GS-9857 with ribavirin.
Cohort
2. Two groups of DAA-experienced patients-those with and without cirrhosis-were enrolled in cohort 2. Both groups received 12 weeks of sofosbuvirvelpatasvir plus GS-9857. The protocol specified that if the rate of relapse in either group was 10% or less, there was an option that another group of patients could be enrolled to receive 8 weeks of treatment. This option was not exercised.
Patients.
Enrollment was open to patients at least 18 years of age chronically infected with genotype 1 HCV with serum HCV levels of at least 10,000 IU/mL. Cirrhosis was defined as any one of the following: biopsy showing cirrhosis (Metavir score of 4 or Ishak score of !5), transient elastography (FibroScan; Echosens, Paris, France) result greater than 12.5 kPa, or a FibroTest (Biopredictive, Paris, France) score greater than 0.75 together with an aspartate aminotransferase-to-platelet ratio index greater than 2 during screening. Exclusion criteria included a platelet count less than 50,000 cells/mL, hemoglobin level less than 110 g/L for women and less than 120 g/L for men, albumin level less than 30 g/L, creatinine clearance less than 60 mL/min as calculated by the Cockcroft-Gault equation, and prothrombin time or direct bilirubin greater than 1.5 times the upper limit of normal. Patients with evidence of decompensation (ie, clinical ascites, encephalopathy, or variceal hemorrhage) and those with hepatocellular carcinoma were excluded.
Written informed consent was obtained from all patients before enrollment and before any study procedures were performed. The study was approved by the institutional review board or independent ethics committee at all participating sites and was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. The sponsor (Gilead Sciences) collected the data, monitored the study conduct, and performed the statistical analyses. All authors had access to the study data and reviewed and approved the final manuscript.
Procedures
All patients received a fixed-dose combination tablet of sofosbuvir 400 mg and velpatasvir 100 mg once daily, along with a 100-mg tablet of GS-9857 once daily, taken with food. Ribavirin was administered 1000-1200 mg/day (1000 mg for patients weighing <75 kg and 1200 mg for patients weighing !75 kg) in a divided daily dose. This was an open-label study, in which patients were enrolled by investigators at the study centers. No participants or study personnel were blinded to treatment assignments at any time during the study.
Assessments
Serum HCV-RNA concentrations were measured using the COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0 (Roche, Indianapolis, IN) with a lower limit of quantification for HCV RNA of less than 15 IU/mL. HCV genotype and subtype were determined using the Siemens Versant HCV Genotype INNO-LiPA 2.0 assay (Tarrytown, NY). For all patients, the interleukin 28B genotype was determined by polymerase chain reaction amplification and sequencing of the rs12979860 single-nucleotide polymorphism.
Deep sequencing of the NS3A, NS5A, and NS5B regions of the HCV RNA using MiSeq technology (DDL Diagnostic Laboratory, Rijswijk, The Netherlands) was performed at baseline for all patients and at the time of virologic failure for all patients who did not achieve SVR 12 weeks after treatment (SVR12). The resulting sequences were compared with reference sequences or sequences from baseline samples to determine the prevalence of RASs and the association of RASs with virologic outcomes. RASs present at greater than 1% and 15% of sequence reads were reported, unless specified.
Safety was assessed in all patients at all on-treatment visits and for 30 days after the completion of treatment by physical examination and review of adverse events and laboratory test results.
Outcomes
The primary efficacy end point of this study was SVR12 (serum HCV-RNA level <15 IU/mL) in all patients who were enrolled and received at least 1 dose of study drug. The secondary efficacy end points included the proportion of patients with virologic failure. The primary safety end point was any adverse event leading to the permanent discontinuation of study treatment.
Statistical Analysis
For this exploratory phase 2 study we did not plan or conduct any inferential statistics. No formal sample size calculations were used to determine the group size of 30. The SVR12 rate in each of the treatment groups was calculated with 2-sided 95% exact confidence intervals (CIs) based on the Clopper-Pearson method.
Role of the Funding Source
The study sponsor oversaw trial management, data collection, statistical analyses, and the writing and review of the report. All authors had access to the study data and had reviewed and approved the final manuscript.
Results
Of the 247 patients screened, 197 were enrolled and received treatment: 34 treatment-naive patients without cirrhosis, 33 treatment-naive patients with cirrhosis, 31 previously treated patients without cirrhosis, and 32 previously treated patients with cirrhosis ( Supplementary  Figure 1 ). Reasons for screen failure are listed in the Appendix. Baseline characteristics of patients are shown in Table 1 . The groups were balanced overall with regard to baseline characteristics. A majority of patients in all groups were men, of white race, with genotype 1a infection and non-CC interleukin 28B genotypes. Among the DAAexperienced patients in cohort 2, 46% previously received a NS5A inhibitor (ledipasvir, n ¼ 7; daclatasvir, n ¼ 11; other, n ¼ 11) and 54% previously received a NS3/4A protease inhibitor and a NS5B polymerase inhibitor (simeprevir with sofosbuvir, n ¼ 25; other, n ¼ 9).
By week 4 of treatment, 68 of 70 (97%) treatment-naive patients without cirrhosis and 60 of 64 (94%) treatmentnaive patients with cirrhosis had HCV-RNA levels less than 15 IU/mL. Among treatment-experienced patients, 29 of 31 (94%) without cirrhosis and 31 of 32 (97%) with cirrhosis had HCV-RNA levels less than 15 IU/mL by week 4 of treatment. By week 8 of treatment, all patients receiving at least 8 weeks of treatment had a HCV-RNA level less than 15 IU/mL. In treatment-naive patients with cirrhosis, the addition of ribavirin appeared to have no impact on HCV viral kinetics (Table 2) .
Among treatment-naive patients without cirrhosis, rates of SVR12 were 71% (24 of 34; 95% CI, 53-85) in patients receiving 6 weeks of treatment, and 100% (36 of 36; 95% CI, 90-100) in patients receiving 8 weeks of treatment ( Table 2 ). Among treatment-naive patients with cirrhosis, rates of SVR12 were 94% (31 of 33; 95% CI, 80-99) in patients receiving 8 weeks of sofosbuvir-velpatasvir plus GS-9857 and 81% (25 of 31; 95% CI, 63-93) in patients receiving 8 weeks of sofosbuvir-velpatasvir plus GS-9857 with ribavirin ( Table 2 ). Among patients previously treated with DAA-containing regimen(s), rates of SVR12 were 100% (31 of 31; 95% CI, 89-100) in patients without cirrhosis receiving 12 weeks of treatment, and 100% (32 of 32; 95% CI, 89-100) in patients with cirrhosis receiving 12 weeks of treatment. Across the groups, no significant differences in SVR12 rates were observed based on baseline differences (Appendix). Eighteen patients with virologic failure relapsed after the end of treatment; no patient had a virologic breakthrough during treatment (Appendix).
Baseline sequencing was available for 197 of the 197 patients enrolled in the study. Overall, 63% (84 of 134) of treatment-naive and 83% (52 of 63) of DAA-experienced patients had baseline class RASs in at least 1 of the 3 target genes (NS3, NS5A, and NS5B), with a 1% deep sequencing assay cut-off level ( Table 3 ). Among the DAA-experienced patients, 93% (27 of 29) of the NS5A inhibitor-experienced patients had NS5A RASs, as compared with 21% (7 of 34) of DAA-experienced patients who were not treated previously with an NS5A inhibitor (data not shown). Table 3 shows the SVR rates for patients without RASs and with single and multiclass NS3, NS5A, and NS5B RASs with a 1% sequencing cut-off level. In treatment-naive patients, 8 weeks of treatment with sofosbuvir-velpatasvir plus GS-9857 without ribavirin led to SVR12 in 96% (23 of 24) and 98% (44 of 45) of patients without and with baseline RASs, respectively. Use of a 15% sequencing cut-off level led to a similar result (Supplementary Material). All DAA-experienced patients, regardless of the presence of single or multiclass RASs, achieved SVR12 after 12 weeks of treatment with sofosbuvir-velpatasvir plus GS-9857. There were 12 DAA-experienced patients with the NS5A RAS Y93H/N at baseline, all of whom achieved SVR12.
Sequencing data were available for all 18 treatment-naive patients who relapsed. Eleven of 18 patients (61%) had the same number of or fewer RASs at the time of virologic relapse than at baseline. Four of 18 patients (22%) had no RASs both at baseline and at virologic relapse. Only 3 patients had treatment-emergent RASs, all in the NS3 gene and all at frequencies less than 2% of the viral population. The treatmentemergent NS3 RASs included V170T, Q41R/A156T, and V36M. Of these, only A156T resulted in in vitro resistance to GS-9857 (confers an w500-fold shift in median effective concentration in genotype 1a and 1b replicon assays).
The most common adverse events were headache, nausea, fatigue, and diarrhea (Table 4 ). Overall, 64% of patients experienced at least 1 adverse event. Patients in the ribavirin-containing group had higher rates of fatigue (32%) and anemia (23%) than patients in the other groups. Two patients, both in the group of treatment-naive patients with cirrhosis receiving 8 weeks of treatment without ribavirin, had treatment-emergent serious adverse events: a 61-yearold white woman with valvular disease experienced atrial flutter on day 35 of treatment, and a 67-year-old white woman had vertigo on post-treatment day 26. One patient discontinued treatment because of adverse events. This patient, a 50-year-old black woman with cirrhosis who was receiving sofosbuvir-velpatasvir plus GS-9857 with ribavirin, stopped study treatment on day 24 after having confirmed abnormally high levels of alanine aminotransferase (ALT) (grade 3) and aspartate aminotransferase (grade 2). A single grade 1 increase in total bilirubin was observed at study treatment week 2, and remained within normal limits at all other timepoints. Aminotransferase levels returned to normal 4 weeks after stopping the study drug. An evaluation for acute causes of hepatitis was negative. Another patient in the same treatment group discontinued ribavirin after experiencing diarrhea, nausea, vomiting, and rib soreness on day 2 of treatment. This patient continued sofosbuvir-velpatasvir plus GS-9857 without ribavirin and achieved SVR12.
One treatment-naive patient with cirrhosis who received 8 weeks of treatment died on day 175 of follow-up evaluation. The cause of death was atypical pneumonia.
Overall, 19 patients (10%) had grade 3 laboratory abnormalities and 2 patients (1%) had grade 4 laboratory abnormalities. Grades 3 and 4 laboratory abnormalities occurred almost exclusively in patients with cirrhosis. There were 4 patients with cirrhosis who had postbaseline hemoglobin values less than 10 g/dL; all were receiving ribavirin. One patient (mentioned earlier) had a grade 3 ALT increase (>5 Â upper limit of normal [ULN]). No patient had a grade 2 ALT increase (an increase of >2.5 to 5 Â ULN) and 2 patients (both cirrhotic) had a grade 1 ALT increase (increases to 1.25-2.5 Â ULN).
Discussion
The development of oral DAAs represents a major advance in the treatment of HCV in patients of all genotypes. Currently available DAA combination regimens offer SVR rates well over 90% overall and in most patient subpopulations. Nevertheless, some patients do not achieve SVR with existing regimens. Patients who have failed prior treatment with first-generation NS3/4A protease inhibitors (eg, telaprevir, boceprevir, or simeprevir) may be re-treated with ledipasvir-sofosbuvir, but patients who have been treated unsuccessfully with a regimen that includes an NS5A inhibitor have no approved re-treatment options. In a previous trial, patients with genotype 1 HCV who did not achieve SVR after 8 or 12 weeks of ledipasvirsofosbuvir-based regimens and subsequently were re-treated with 24 weeks of ledipasvir-sofosbuvir had an SVR12 rate of only 71%. In this population, the presence of baseline NS5A RASs was associated with a higher rate of November 2016 SOF/VEL Plus GS-9857 in HCV GT 1 897 CLINICAL LIVER virologic failure. 18 In another small trial, 14 of 16 patients (88%) who previously failed a daclatasvir-containing regimen achieved SVR12 after re-treatment with simeprevir-sofosbuvir for 12 weeks. Thirteen of the 16 patients had NS5A RASs at baseline, and, of these 13, 11 (85%) achieved SVR12. The 2 patients who did not achieve SVR12 had Q30K and L31M substitutions as the dominant viral populations at re-treatment baseline. 19 In this open-label, phase 2 study, 12 weeks of treatment with sofosbuvir-velpatasvir plus GS-9857 was safe and highly effective in patients with HCV genotype 1, with and without cirrhosis, who did not achieve SVR after prior treatment with DAAs, including those who previously received an NS5A inhibitor. In treatment-naive patients, the 8-week regimen was safe and effective, regardless of cirrhosis status. Among the treatment-naive patients who relapsed, the presence of baseline RASs appeared to have no impact on treatment outcome. Treatment-emergent RASs by deep sequencing with a 1% cut-off rate were rare (3 of 18; 17%), and no treatment-emergent RASs among relapsers were detected with the 15% cut-off level. This is consistent with the anticipated high barrier of resistance of the combination therapy based on in vitro data. 20 Treatment-naive patients without cirrhosis treated for 8 weeks achieved a SVR12 rate of 100%, which was higher than results reported in a recent study of combining 3 DAAs for treatment for the same population and treatment duration. 21 Treatment-naive patients with cirrhosis treated for 8 weeks had lower SVR12 rates (81%-94%) than patients without cirrhosis. Larger studies will determine whether this short duration is adequate for this patient population.
One unexpected result in our trial was the apparent lack of benefit of the addition of ribavirin to sofosbuvirvelpatasvir plus GS-9857 for treatment-naive patients with cirrhosis. Although patients in this group receiving ribavirin had a numerically lower rate of SVR12 than treatment-naive patients with cirrhosis who received sofosbuvir-velpatasvir plus GS-9857 without ribavirin (81% vs 94%), the confidence intervals overlap and it is likely that this reflects the small sample sizes.
Factors limiting the interpretation of the results of this trial include its small size and the uncontrolled, open-label design. Although the trial enrolled only patients with genotype 1 HCV, another trial of similar design has been conducted to assess this combination regimen in patients with non-genotype 1 HCV.
In conclusion, sofosbuvir-velpatasvir plus GS-9857 for 12 weeks provided a high rate of SVR12 (100%) and was well tolerated in a group of patients currently without treatment options-those with and without compensated cirrhosis who have not achieved SVR after previous treatment with a NS5A inhibitor-containing regimen. The addition of GS-9857 to sofosbuvir-velpatasvir also was safe in the treatmentnaive population, in whom it was effective in reducing the treatment duration to 8 weeks while preserving a high rate of SVR12. These 3 potent pangenotypic DAAs have been co-formulated into a fixed-dose combination tablet. The phase 3 program will evaluate this fixed-dose combination Includes patients with the NS3 RAS Q80K. November 2016 SOF/VEL Plus GS-9857 in HCV GT 1 899 CLINICAL LIVER for 8 weeks in treatment-naive patients and for 12 weeks in DAA-experienced patients, including those who previously have received an NS5A inhibitor.
